{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:40:55Z","timestamp":1784601655258,"version":"3.55.0"},"publisher-location":"Cham","reference-count":109,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319521732","type":"print"},{"value":"9783319521756","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/164_2016_69","type":"book-chapter","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T12:41:22Z","timestamp":1477572082000},"page":"197-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Bifunctional Drugs for the Treatment of Respiratory Diseases"],"prefix":"10.1007","author":[{"given":"Clive","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,28]]},"reference":[{"key":"69_CR1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)61449-X","volume":"372","author":"IM Adcock","year":"2008","unstructured":"Adcock IM, Caramori G, Chung KF (2008) New targets for drug development in asthma. Lancet 372:1073\u20131087","journal-title":"Lancet"},{"key":"69_CR2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejphar.2012.07.002","volume":"691","author":"AS Ahmedat","year":"2012","unstructured":"Ahmedat AS, Warnken M, Juergens UR et al (2012) \u03b22-adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in human lung fibroblasts. Eur J Pharmacol 691:218\u2013224","journal-title":"Eur J Pharmacol"},{"key":"69_CR3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0022-3565(24)37837-1","volume":"287","author":"Y Arakida","year":"1998","unstructured":"Arakida Y, Suwa K, Ohga K et al (1998) In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther 287:633\u2013639","journal-title":"J Pharmacol Exp Ther"},{"key":"69_CR4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1081\/JAS-100107539","volume":"38","author":"K Baba","year":"2001","unstructured":"Baba K, Sakakibara A, Yagi T et al (2001) Effects of theophylline withdrawal in well-controlled asthmatics treated with inhaled corticosteroid. J Asthma 38:615\u2013624","journal-title":"J Asthma"},{"key":"69_CR5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2125.1998.t01-1-00689.x","volume":"45","author":"PG Bardin","year":"1998","unstructured":"Bardin PG, Dorward MA, Lampe FC et al (1998) Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 45:387\u2013391","journal-title":"Br J Clin Pharmacol"},{"key":"69_CR6","doi-asserted-by":"crossref","unstructured":"Barnes N, Grape S, Fox JC, Fitzgerland M, Snell N, Pavord ID, Jeffery P, Qui Y, Singh D, Antczak A, Nizankowska-Mogilnicka E (2010) Effects of low dose inhaled theophylline (ADC 4022) co-administered with budesonide on inflammatory markers and lung function in patients with COPD. American Thoracic Society Abstract, Annual Conference","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A4470"},{"key":"69_CR7","first-page":"A4249","volume":"181","author":"EG Barrett","year":"2010","unstructured":"Barrett EG, Rudolph K, Royer C et al (2010) A novel mutual prodrug of salmeterol and desisobutrylciclesonide attenuates acute bronchoconstriction in the absence of cardiovascular side-effects in ragweed sensitized and naive dogs [abstract]. Am J Respir Crit Care Med 181:A4249","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1183\/09031936.00138707","volume":"31","author":"ED Bateman","year":"2008","unstructured":"Bateman ED, Hurd SS, Barnes PJ et al (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31:143\u2013178","journal-title":"Eur Respir J"},{"key":"69_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.pupt.2013.03.015","volume":"26","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Kornmann O, Ambery C et al (2013) Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 26:581\u2013587","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"69_CR10","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2006.02.045","volume":"117","author":"V Boswell-Smith","year":"2006","unstructured":"Boswell-Smith V, Cazzola M, Page CP (2006a) Are PDE4 inhibitors just more theophylline? J Allergy Clin Immunol 117(6):1237\u20131243","journal-title":"J Allergy Clin Immunol"},{"key":"69_CR11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/jpet.105.099192","volume":"318","author":"V Boswell-Smith","year":"2006","unstructured":"Boswell-Smith V, Spina D, Oxford AW et al (2006b) The pharmacology of two novel long-acting phosphodiesterase 3\/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropy. J Pharmacol Exp Ther 318:840\u2013848","journal-title":"J Pharmacol Exp Ther"},{"key":"69_CR12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.rmed.2009.02.011","volume":"103","author":"L-P Boulet","year":"2009","unstructured":"Boulet L-P, Lemi\u00e8re C, Gauvreau G et al (2009) Safety, pharmacodynamics and pharmacokinetics of TPI 1020 in smokers with asthma. Respir Med 103:1159\u20131166","journal-title":"Respir Med"},{"key":"69_CR13","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1183\/09031936.00184511","volume":"39","author":"L-P Boulet","year":"2012","unstructured":"Boulet L-P, FitzGerald JM, Levy ML et al (2012) A guide to the translation of the Global Initiative for Asthma (GINA) strategy into improved care. Eur Respir J 39:1220\u20131229","journal-title":"Eur Respir J"},{"key":"69_CR14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.93.05080982","volume":"5","author":"T Brunn\u00e9e","year":"1992","unstructured":"Brunn\u00e9e T, Engelst\u00e4tter R, Steinijans VW, Kunkel G (1992) Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 5:982\u2013985","journal-title":"Eur Respir J"},{"key":"69_CR15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/S0140-6736(00)03497-8","volume":"356","author":"SA Bryan","year":"2000","unstructured":"Bryan SA, O\u2019Connor BJ, Matti S et al (2000) Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2149\u20132153","journal-title":"Lancet"},{"key":"69_CR16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","volume":"374","author":"PMA Calverley","year":"2009","unstructured":"Calverley PMA, Rabe KF, Goehring U-M et al (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685\u2013694","journal-title":"Lancet"},{"key":"69_CR17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.113.204644","volume":"346","author":"L Calzetta","year":"2013","unstructured":"Calzetta L, Page CP, Spina D et al (2013) Effect of the mixed phosphodiesterase 3\/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther 346:414\u2013423","journal-title":"J Pharmacol Exp Ther"},{"key":"69_CR18","doi-asserted-by":"crossref","unstructured":"Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG (2015) Pharmacological chemochestion of the interaction between the dual PDE 3 \/ 4 inhibitor RPL554 and glycopyronim on human isolated bronchi and small airways. Pulm Pharmacol Ther 32:15\u201323","DOI":"10.1016\/j.pupt.2015.03.007"},{"key":"69_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1590\/S0100-879X2006000200016","volume":"39","author":"HS Campos","year":"2006","unstructured":"Campos HS, Xisto DG, Oliveira MB et al (2006) Protective effects of phosphodiesterase inhibitors on lung function and remodelling in a murine model of chronic asthma. Braz J Med Biol Res 39:283\u2013287","journal-title":"Braz J Med Biol Res"},{"key":"69_CR20","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1517\/14656566.2014.972367","volume":"15","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Matera MG (2014) Triple combinations in chronic obstructive pulmonary disease \u2013 is three better than two? Expert Opin Pharmacol 15:2475\u20132478","journal-title":"Expert Opin Pharmacol"},{"key":"69_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","volume":"23","author":"M Cazzola","year":"2010","unstructured":"Cazzola M, Molimard M (2010) The scientific rationale for combining long acting \u03b22 agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 23:257\u2013267","journal-title":"Pulm Pharmacol Ther"},{"key":"69_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pupt.2009.10.002","volume":"23","author":"M Cazzola","year":"2010","unstructured":"Cazzola M, Floriani I, Page CP (2010) The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta analysis of induced patient data. Pulm Pharm Ther 23:135\u2013144","journal-title":"Pulm Pharm Ther"},{"key":"69_CR23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG (2012a) Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 64:450\u2013504","journal-title":"Pharmacol Rev"},{"key":"69_CR24","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1183\/09031936.00213711","volume":"40","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG (2012b) Emerging anti-inflammatory strategies for COPD. Eur Respir J 40:724\u2013741","journal-title":"Eur Respir J"},{"key":"69_CR25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2147\/DDDT.S39449","volume":"7","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Segreti A, Matera MG (2013a) New developments in the combination treatment of COPD: focus on umeclidinium\/vilanterol. Drug Des Devel Ther 7:1201\u20131208","journal-title":"Drug Des Devel Ther"},{"key":"69_CR26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1183\/09031936.00067013","volume":"42","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Lopez-Campos JL, Puente-Maestu L (2013b) The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J 42:885\u2013887","journal-title":"Eur Respir J"},{"key":"69_CR27","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.coph.2011.09.002","volume":"11","author":"S Chan","year":"2011","unstructured":"Chan S, Yan C (2011) PDE1 isozymes, key regulators of pathological vascular remodeling. Curr Opin Pharmacol 11:720\u2013724","journal-title":"Curr Opin Pharmacol"},{"key":"69_CR28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1378\/chest.120.1.305","volume":"120","author":"NB Charan","year":"2001","unstructured":"Charan NB (2001) Does sildenafil also improve breathing? Chest 120:305\u2013306","journal-title":"Chest"},{"key":"69_CR29","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1365-2133.2010.10029.x","volume":"163","author":"MK Church","year":"2010","unstructured":"Church MK (2010) Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 163:1330\u20131332","journal-title":"Br J Dermatol"},{"key":"69_CR30","first-page":"245","volume":"66","author":"S Crescioli","year":"1991","unstructured":"Crescioli S, Spinazzi A, Plebani M et al (1991) Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects. Ann Allergy 66:245\u2013251","journal-title":"Ann Allergy"},{"key":"69_CR31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1164\/rccm.2105106","volume":"165","author":"SV Culpitt","year":"2002","unstructured":"Culpitt SV, de Matos C, Russell RE et al (2002) Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165:1371\u20131376","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1517\/13543784.2013.801958","volume":"22","author":"R Dawson","year":"2013","unstructured":"Dawson R, Diacon A (2013) PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin Investig Drugs 22:927\u2013932","journal-title":"Expert Opin Investig Drugs"},{"key":"69_CR33","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJM199711133372002","volume":"337","author":"DJ Evans","year":"1997","unstructured":"Evans DJ, Taylor DA, Zetterstrom O et al (1997) A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337:1412\u20131418","journal-title":"N Engl J Med"},{"key":"69_CR34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","volume":"374","author":"LM Fabbri","year":"2009","unstructured":"Fabbri LM, Calverley PMA, Izquierdo-Alonso JL et al (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 374:695\u2013703","journal-title":"Lancet"},{"key":"69_CR35","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/COH.0000000000000011","volume":"8","author":"C Flexner","year":"2013","unstructured":"Flexner C, Saag M (2013) The antiretroviral drug pipeline: prospects and implications for future treatment research. Curr Opin HIV AIDS 8:572\u2013578","journal-title":"Curr Opin HIV AIDS"},{"key":"69_CR36","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1378\/chest.09-2363","volume":"137","author":"PA Ford","year":"2010","unstructured":"Ford PA, Durham AL, Russell REK et al (2010) Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:1338\u20131344","journal-title":"Chest"},{"key":"69_CR37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.1992.tb05658.x","volume":"34","author":"RW Foster","year":"1992","unstructured":"Foster RW, Rakshi K, Carpenter JR, Small RC (1992) Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21\u2013132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol 34:527\u2013534","journal-title":"Br J Clin Pharmacol"},{"key":"69_CR38","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","volume":"1","author":"LG Franciosi","year":"2013","unstructured":"Franciosi LG, Diamant Z, Banner KH et al (2013) Efficacy and safety of RPL 554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 1:714\u2013727","journal-title":"Lancet Respir Med"},{"issue":"1","key":"69_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/cea.12235","volume":"44","author":"GM Gauvreau","year":"2014","unstructured":"Gauvreau GM, Boulet L-P, Cockcroft DW et al (2014) OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy 44(1):29\u201337. doi:10.1111\/cea.12235","journal-title":"Clin Exp Allergy"},{"key":"69_CR40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.coph.2005.04.001","volume":"5","author":"MA Giembycz","year":"2005","unstructured":"Giembycz MA (2005) Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 5:238\u2013244","journal-title":"Curr Opin Pharmacol"},{"key":"69_CR41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.coph.2014.04.001","volume":"16","author":"MA Giembycz","year":"2014","unstructured":"Giembycz MA, Maurice DH (2014) Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease. Curr Opin Pharmacol 16:89\u2013107","journal-title":"Curr Opin Pharmacol"},{"key":"69_CR42","unstructured":"Goodman & Gilman (2005) The pharmacological basis of therapeutics. In: Brunton LL, Lazo JS, Parker KL (eds), 11th edn. McGraw Hill, pp 717\u2013736"},{"key":"69_CR43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1094-5539(02)00172-4","volume":"16","author":"DC Grootendorst","year":"2003","unstructured":"Grootendorst DC, Gauw SA, Benschop N et al (2003) Efficacy of the novel phosphodiesterase 4 inhibitor BAY 19\u20138004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther 16:115\u2013120","journal-title":"Pulm Pharmacol Ther"},{"key":"69_CR44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/thx.2006.075937","volume":"62","author":"DC Grootendorst","year":"2007","unstructured":"Grootendorst DC, Gauw SA, Verhoosel RM et al (2007) Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62:1081\u20131087","journal-title":"Thorax"},{"key":"69_CR45","first-page":"A6557","volume":"189","author":"IH Guimaraes","year":"2014","unstructured":"Guimaraes IH, Padilha GDA, Lopes-Pacheco M et al (2014) Therapy with a new phosphodiesterase 4 and 5 inhibitor in experimental elastase-induced emphysema (abstract). Am J Respir Crit Care Med 189:A6557","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR46","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1183\/09031936.97.10051008","volume":"10","author":"PL Harbinson","year":"1997","unstructured":"Harbinson PL, MacLeod D, Hawksworth R et al (1997) The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 10:1008\u20131014","journal-title":"Eur Respir J"},{"issue":"12","key":"69_CR47","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.clinthera.2013.10.002","volume":"35","author":"Z-B Huang","year":"2013","unstructured":"Huang Z-B, Zhao S-S, Huang Y et al (2013) Comparison of the efficacy of lamivudine plus adefovir versus entecavir in the treatment of lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Clin Ther 2013 35(12):1997\u20132006. doi:10.1016\/j.clinthera.2013.10.002","journal-title":"Clin Ther 2013"},{"key":"69_CR48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bmcl.2013.11.028","volume":"24","author":"L Huang","year":"2014","unstructured":"Huang L, Shan W, Zhou Q et al (2014) Design synthesis and evaluation of dual pharmacology \u03b22-adrenoceptor agonists and PDE4 inhibitors. Bioorg Med Chem Lett 24:249\u2013253","journal-title":"Bioorg Med Chem Lett"},{"key":"69_CR49","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4155\/fmc.11.106","volume":"3","author":"AD Hughes","year":"2011","unstructured":"Hughes AD, Jones LH (2011) Dual-pharmacology muscarinic antagonist and \u03b22-agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem 3:1585\u20131605","journal-title":"Future Med Chem"},{"key":"69_CR50","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1183\/09031936.96.09030456","volume":"9","author":"ZH Jaffar","year":"1996","unstructured":"Jaffar ZH, Sullivan P, Page C, Costello J (1996) Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Respir J 9:456\u2013462","journal-title":"Eur Respir J"},{"key":"69_CR51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1165\/rcmb.2012-0500OC","volume":"49","author":"MT Kasaian","year":"2013","unstructured":"Kasaian MT, Marquette K, Fish S et al (2013) An IL-4\/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice. Am J Respir Cell Mol Biol 49:37\u201346","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"69_CR52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/ACI.0000000000000108","volume":"14","author":"AL Kau","year":"2014","unstructured":"Kau AL, Korenblat PE (2014) Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes. Curr Opin Allergy Clin Immunol 14(6):570\u2013575","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"69_CR53","doi-asserted-by":"crossref","unstructured":"Kew KM, Seniukovich A (2014) Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (3):CD010115","DOI":"10.1002\/14651858.CD010115.pub2"},{"key":"69_CR54","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1164\/ajrccm.151.6.7767539","volume":"151","author":"J Kidney","year":"1995","unstructured":"Kidney J, Dominguez M, Taylor M et al (1995) Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 151:1907\u20131914","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR55","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2332\/allergolint.08-OA-0053","volume":"58","author":"T Kita","year":"2009","unstructured":"Kita T, Fujimura M, Myou S et al (2009) Effects of KF19514, a phosphodiesterase 4 and 1 inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma. Allergol Int 58:267\u2013275","journal-title":"Allergol Int"},{"key":"69_CR56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.103.061739","volume":"310","author":"V Lagente","year":"2004","unstructured":"Lagente V, Naline E, Guenon I et al (2004) A nitric oxide-releasing salbutamol elicits potent relaxant and anti-inflammatory activities. J Pharmacol Exp Ther 310:367\u2013375","journal-title":"J Pharmacol Exp Ther"},{"key":"69_CR57","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","volume":"356","author":"MJ Leckie","year":"2000","unstructured":"Leckie MJ, ten Brinke A, Khan J et al (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144\u20132148","journal-title":"Lancet"},{"key":"69_CR58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/ajrccm.164.2.2006043","volume":"164","author":"S Lim","year":"2001","unstructured":"Lim S, Tomita K, Caramori G et al (2001) Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 164:273\u2013276","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR59","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.bmcl.2012.11.058","volume":"23","author":"A Liu","year":"2013","unstructured":"Liu A, Huang L, Wang Z et al (2013) Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual \u03b22-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD. Bioorg Med Chem Lett 23:1548\u20131552","journal-title":"Bioorg Med Chem Lett"},{"issue":"14","key":"69_CR60","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Waltz H, Tetzlaff K, Towse L, Finnegan H, Dahl R, Decramer M, Chanez P, Wouters EFM, Calverley PMA (2014) Withdrawal of inhibited glucocorticosteroids of COPD. N Engl J Med 371(14):1285\u20131294","journal-title":"N Engl J Med"},{"key":"69_CR61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0014-2999(93)90519-N","volume":"249","author":"S Manzini","year":"1993","unstructured":"Manzini S, Perretti F, Abelli L et al (1993) Isbufylline, a new xanthine derivative, inhibits airway hyperresponsiveness and airway inflammation in guinea pigs. Eur J Pharmacol 249:251\u2013257","journal-title":"Eur J Pharmacol"},{"key":"69_CR62","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s40265-014-0303-8","volume":"74","author":"MG Matera","year":"2014","unstructured":"Matera MG, Rogliani P, Calzetta L, Cazzola M (2014) Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? Drugs 74:1983\u20131992","journal-title":"Drugs"},{"key":"69_CR63","first-page":"A5698","volume":"185","author":"JD McDonald","year":"2012","unstructured":"McDonald JD, Doyle-Eisele M, Kuehl PJ et al (2012) GS-5759, a novel bi-functional phosphodiesterase 4 inhibitor and long-acting \u03b22-adrenoreceptor agonist: evaluation of its bronchodilator and anti-inflammatory pharmacology in non-human primates [abstract]. Am J Respir Crit Care Med 185:A5698","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pupt.2012.06.007","volume":"25","author":"A McNamara","year":"2012","unstructured":"McNamara A, Steinfeld T, Pulido-Rios MT et al (2012) Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and \u03b22-adrenoceptor agonist (MABA). Pulm Pharmacol Ther 25:357\u2013363","journal-title":"Pulm Pharmacol Ther"},{"key":"69_CR65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pupt.2012.07.003","volume":"26","author":"H Meurs","year":"2013","unstructured":"Meurs H, Dekkers BG, Maarsingh H et al (2013a) Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther 26:145\u2013155","journal-title":"Pulm Pharmacol Ther"},{"key":"69_CR66","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.coph.2013.04.004","volume":"13","author":"H Meurs","year":"2013","unstructured":"Meurs H, Oenema TA, Kistemaker LE, Gosens R (2013b) A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol 13:316\u2013323","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl 3","key":"69_CR67","first-page":"57","volume":"28","author":"K Minoguchi","year":"1998","unstructured":"Minoguchi K, Kohno Y, Oda N et al (1998) Effect of theophylline withdrawal on airway inflammation in asthma. Clin Exp Allergy 28(Suppl 3):57\u201363","journal-title":"Clin Exp Allergy"},{"key":"69_CR68","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/ajrccm.160.3.9812065","volume":"160","author":"S Myou","year":"1999","unstructured":"Myou S, Fujimura M, Kamio Y et al (1999) Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 160:817\u2013820","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR69","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","volume":"360","author":"P Nair","year":"2009","unstructured":"Nair P, Pizzichini MM, Kjarsgaard M et al (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360:985\u2013993","journal-title":"N Engl J Med"},{"key":"69_CR70","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","volume":"42","author":"P Nair","year":"2012","unstructured":"Nair P, Gaga M, Zervas E et al (2012) Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42:1097\u20131103","journal-title":"Clin Exp Allergy"},{"key":"69_CR71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-6147(91)90484-A","volume":"12","author":"CD Nicholson","year":"1991","unstructured":"Nicholson CD, Challiss RA, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19\u201327","journal-title":"Trends Pharmacol Sci"},{"key":"69_CR72","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pupt.2013.03.009","volume":"26","author":"V Norris","year":"2013","unstructured":"Norris V, Ambery C (2013) Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Pulm Pharmacol Ther 26:574\u2013580","journal-title":"Pulm Pharmacol Ther"},{"key":"69_CR73","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bmcl.2012.08.121","volume":"23","author":"K Ochiai","year":"2013","unstructured":"Ochiai K, Takita S, Kojima A et al (2013) Phosphodiesterase inhibitors. Part 5: hybrid PDE3\/4 inhibitors as dual bronchorelaxant\/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett 23:375\u2013381","journal-title":"Bioorg Med Chem Lett"},{"key":"69_CR74","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pupt.2010.04.002","volume":"23","author":"CP Page","year":"2010","unstructured":"Page CP (2010) Doxophylline: a \u201cnovophylline\u201d. Pulm Pharmacol Ther 23:231\u2013234","journal-title":"Pulm Pharmacol Ther"},{"key":"69_CR75","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000368800","volume":"165","author":"CP Page","year":"2014","unstructured":"Page CP (2014) Phosphodiesterase inhibitors for the treatment of asthma and COPD. Int Arch Allergy Immunol 165:152\u2013164","journal-title":"Int Arch Allergy Immunol"},{"key":"69_CR76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.coph.2012.02.016","volume":"12","author":"CP Page","year":"2012","unstructured":"Page CP, Spina D (2012) Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 12:275\u2013286","journal-title":"Curr Opin Pharmacol"},{"key":"69_CR77","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0091-6749(85)90779-1","volume":"76","author":"R Pauwels","year":"1985","unstructured":"Pauwels R, Van Renterghem D, Van der Straeten M et al (1985) The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 76:583\u2013590","journal-title":"J Allergy Clin Immunol"},{"key":"69_CR78","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.coph.2014.03.005","volume":"16","author":"T Pera","year":"2014","unstructured":"Pera T, Penn RB (2014) Crosstalk between beta 2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol 16:72\u201381","journal-title":"Curr Opin Pharmacol"},{"key":"69_CR79","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/thx.40.12.881","volume":"40","author":"CG Persson","year":"1985","unstructured":"Persson CG (1985) On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter. Thorax 40:881\u2013886","journal-title":"Thorax"},{"key":"69_CR80","first-page":"209","volume":"47","author":"G Phillips","year":"2012","unstructured":"Phillips G, Salmon M (2012) Bifunctional compounds for the treatment of COPD. Annu Rep Med Chem 47:209\u2013222","journal-title":"Annu Rep Med Chem"},{"key":"69_CR81","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bbadis.2012.03.002","volume":"1822","author":"M Profita","year":"2012","unstructured":"Profita M, Bonanno A, Montalbano AM et al (2012) \u03b22 long-acting and anticholinergic drugs control TGF-\u03b21-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta 1822:1079\u20131089","journal-title":"Biochim Biophys Acta"},{"key":"69_CR82","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.imbio.2014.01.004","volume":"219","author":"M Profita","year":"2014","unstructured":"Profita M, Albano GD, Riccobono L, Di Sano C, Montalbano AM, Gagliardo R, Anzalone G, Bonanno A, Pieper MP, Gjomarkaj M (2014) Increased levels of Th17 cells are associated with non-neuronal acetylcholine in COPD patients. Immunobiology 219:392\u2013401","journal-title":"Immunobiology"},{"key":"69_CR83","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1016\/j.bmcl.2007.03.047","volume":"17","author":"L Provins","year":"2007","unstructured":"Provins L, Christophe B, Danhaive P et al (2007) Dual M3 antagonists\u2013PDE4 inhibitors. Part 2: synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg Med Chem Lett 17:3077\u20133080","journal-title":"Bioorg Med Chem Lett"},{"key":"69_CR84","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.coph.2012.01.015","volume":"12","author":"I Rahman","year":"2012","unstructured":"Rahman I, MacNee W (2012) Anti oxidant pharmacological therapies for COPD. Curr Opin Pharmacol 12:256\u2013265","journal-title":"Curr Opin Pharmacol"},{"key":"69_CR85","doi-asserted-by":"crossref","first-page":"e56867","DOI":"10.1371\/journal.pone.0056867","volume":"8","author":"F Rieder","year":"2013","unstructured":"Rieder F, Siegmund B, Bundschuh DS et al (2013) The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3\/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. PLoS One 8:e56867","journal-title":"PLoS One"},{"key":"69_CR86","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1183\/09031936.03.00108603","volume":"22","author":"PR Rocco","year":"2003","unstructured":"Rocco PR, Momesso DP, Figueira RC et al (2003) Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury. Eur Respir J 22:20\u201327","journal-title":"Eur Respir J"},{"key":"69_CR87","first-page":"34","volume":"14","author":"F Saint-Martin","year":"2004","unstructured":"Saint-Martin F, Dumur JP, P\u00e9rez I, Izquierdo I (2004) A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 14:34\u201340","journal-title":"J Investig Allergol Clin Immunol"},{"key":"69_CR88","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/13543780903179294","volume":"18","author":"RM Seguin","year":"2009","unstructured":"Seguin RM, Ferrari N (2009) Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 18:1505\u20131517","journal-title":"Expert Opin Investig Drugs"},{"key":"69_CR89","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1465-9921-11-26","volume":"11","author":"D Singh","year":"2010","unstructured":"Singh D, Petavy F, Macdonald AJ et al (2010) The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 11:26","journal-title":"Respir Res"},{"key":"69_CR90","doi-asserted-by":"crossref","first-page":"26583","DOI":"10.1074\/jbc.M113.480483","volume":"288","author":"C Spiess","year":"2013","unstructured":"Spiess C, Bevers J III, Jackman J et al (2013) Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem 288:26583\u201326593","journal-title":"J Biol Chem"},{"issue":"Suppl 3","key":"69_CR91","first-page":"24","volume":"28","author":"D Spina","year":"1998","unstructured":"Spina D, Landells LJ, Page CP (1998) The role of theophylline and phosphodiesterase isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy 28(Suppl 3):24\u201334","journal-title":"Clin Exp Allergy"},{"key":"69_CR92","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000195939","volume":"58","author":"A Spinelli","year":"1991","unstructured":"Spinelli A, Fanelli A, Gorini M et al (1991) Control of breathing in patients with chronic pulmonary obstructive disease: response to bamiphylline. Respiration 58:241\u2013248","journal-title":"Respiration"},{"key":"69_CR93","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.rmed.2005.03.002","volume":"99","author":"DA Stempel","year":"2005","unstructured":"Stempel DA, Stoloff SW, Carranza Rosenzweig JR et al (2005) Adherence to asthma controller medication regimens. Respir Med 99:1263\u20131267","journal-title":"Respir Med"},{"key":"69_CR94","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0140-6736(94)90127-9","volume":"343","author":"P Sullivan","year":"1994","unstructured":"Sullivan P, Bekir S, Jaffar Z et al (1994) Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343:1006\u20131008","journal-title":"Lancet"},{"key":"69_CR95","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pupt.2012.01.003","volume":"25","author":"SL Tannheimer","year":"2012","unstructured":"Tannheimer SL, Sorensen EA, Haran AC et al (2012) Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells. Pulm Pharmacol Ther 25:178\u2013184","journal-title":"Pulm Pharmacol Ther"},{"key":"69_CR96","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1476-5381.2010.00975.x","volume":"161","author":"SA Tannu","year":"2010","unstructured":"Tannu SA, Renzetti LM, Tare N et al (2010) Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors. Br J Pharmacol 161:1329\u20131342","journal-title":"Br J Pharmacol"},{"issue":"9","key":"69_CR97","first-page":"MC11","volume":"8","author":"SR Tapadar","year":"2014","unstructured":"Tapadar SR, Das M, Chaudri AD, Basak S, Mahopatra AR (2014) The effect of acebrofylline vs sustained release theophylline in patients with COPD \u2013 A comparative study. J Clin Diagn Res 8(9):MC11\u2013MC14","journal-title":"J Clin Diagn Res"},{"key":"69_CR98","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1164\/rccm.200211-1372OC","volume":"169","author":"TJ Toward","year":"2004","unstructured":"Toward TJ, Smith N, Broadley KJ (2004) Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Care Med 169:227\u2013234","journal-title":"Am J Respir Care Med"},{"key":"69_CR99","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejphar.2010.05.025","volume":"641","author":"DL Turner","year":"2010","unstructured":"Turner DL, Ferrari N, Ford WR et al (2010) TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs. Eur J Pharmacol 641:213\u2013219","journal-title":"Eur J Pharmacol"},{"key":"69_CR100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","volume":"21","author":"T van der Molen","year":"2012","unstructured":"van der Molen T, Cazzola M (2012) Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 21:101\u2013108","journal-title":"Prim Care Respir J"},{"key":"69_CR101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pupt.2011.10.007","volume":"25","author":"J van Mastbergen","year":"2012","unstructured":"van Mastbergen J, Jolas T, Allegra L, Page CP (2012) The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. Pulm Pharmacol Ther 25:55\u201361","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"69_CR102","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2174\/18715206113136660372","volume":"14","author":"H van Meir","year":"2014","unstructured":"van Meir H, Kenter GG, Burggraaf J et al (2014) The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anticancer Agents Med Chem 14(2):190\u2013203. doi:10.2174\/18715206113136660372","journal-title":"Anticancer Agents Med Chem"},{"key":"69_CR103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","volume":"187","author":"J Vestbo","year":"2013","unstructured":"Vestbo J, Hurd SS, Agust\u00ed AG et al (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187:347\u2013365","journal-title":"Am J Respir Crit Care Med"},{"key":"69_CR104","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S2213-2600(13)70211-X","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA (2013) Dual PDE3\/4 inhibition: a novel approach to airway disease? Lancet Respir Med 1:669\u2013670","journal-title":"Lancet Respir Med"},{"key":"69_CR105","first-page":"P3980","volume":"36","author":"S Wenzel","year":"2010","unstructured":"Wenzel S, Ind PW, Otulana BA et al (2010) Inhaled pitrakinra, an IL-4\/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma [abstract]. Eur Respir J 36:P3980","journal-title":"Eur Respir J"},{"key":"69_CR106","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D et al (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368:2455\u20132466","journal-title":"N Engl J Med"},{"key":"69_CR107","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1183\/09031936.00165712","volume":"42","author":"PL Wielders","year":"2013","unstructured":"Wielders PL, Ludwig-Sengpiel A, Locantore N et al (2013) A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J 42:972\u2013981","journal-title":"Eur Respir J"},{"key":"69_CR108","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1183\/09031936.00115412","volume":"42","author":"CY Yick","year":"2013","unstructured":"Yick CY, Zwinderman AH, Kunst PW et al (2013) Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls. Eur Respir J 42:662\u2013670","journal-title":"Eur Respir J"},{"issue":"3","key":"69_CR109","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","volume":"2","author":"JP Zheng","year":"2014","unstructured":"Zheng JP, Wenb FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WJ, Ma LJ, Xia L, Raitieri L, Sardina M, Gao Y, Wang BS, Zhong NS, On Behalf of the PANTHEON Study Group (2014) Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2(3):187\u2013194. doi:10.1016\/S2213-2600(13)70286-8","journal-title":"Lancet Respir Med"}],"container-title":["Handbook of Experimental Pharmacology","Pharmacology and Therapeutics of Asthma and COPD"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2016_69","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T21:54:40Z","timestamp":1749678880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2016_69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319521732","9783319521756"],"references-count":109,"URL":"https:\/\/doi.org\/10.1007\/164_2016_69","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"28 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}